AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04006743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The swaddling and expressed breast milk group
Description: Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
Study NCT06192420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel®
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study NCT06192420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium gel 1%
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study NCT06192420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study NCT04006743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitated tucking and expressed breast milk group
Description: Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
Study NCT02415114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega Q Plus Resveratrol (with 50mg CoQ10)
Description: Omega Q Plus Resveratrol (with 50mg CoQ10)
Study NCT01189760 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA 24 U
Description: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study NCT03184012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite resin strip crowns by 3M company
Description: anterior carious teeth restored with Strip crowns
Study NCT01228227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATORVASTATIN 80 mg
Description: reload of Atorvastatin 80 mg before the procedure
Study NCT01189760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 44 U
Description: 44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
Study NCT01189760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study NCT01189760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study NCT02750709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
Study NCT02750709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
Study NCT03588065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception
Study NCT03588065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception
Study NCT01228227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN 40 mg
Description: reload of rosuvastatin 40 mg before the procedure
Study NCT03588065 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception
Study NCT03588065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICS
Description: The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
Study NCT03588065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONFERENCE
Description: The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
Study NCT03256344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Virally based anti-cancer immunotherapy given by direct injection into tumors.
Study NCT03256344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A monoclonal antibody given by intravenous injection.
Study NCT01120275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO
Study NCT01120275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03699735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bolero B90-SP
Description: Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
Study NCT03699735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bolero B90-SP
Description: Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health centers provide PPFP counseling and services
Description: Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health centers provide PPFP counseling and services
Description: Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
Study NCT01043926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
Study NCT03802916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone DR tablets 1000 mg (Low dosage)
Description: Deferiprone DR tablets 1000 mg
Study NCT03802916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone DR tablets 1000 mg (High dosage)
Description: Deferiprone DR tablets 1000 mg
Study NCT03064009 — intervention group
Intervention type: OTHER
Intervention: Infection
Description: This is an observational trial
Study NCT03947463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block
Description: After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
Study NCT00757016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
Study NCT00757016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution
Study NCT02494492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravitreous administration of regulator T-cells
Description: The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
Study NCT04433195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test
Description: Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
Study NCT04433195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Xpert MTB/RIF test
Description: Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
Study NCT01955551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
Study NCT01955551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anticipatory Guidance on Child Development
Description: In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEWs provide PPFP counseling and services
Description: HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteers (Development Army) promote PPFP
Description: HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health centers conduct data reviews
Description: Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health centers conduct data reviews
Description: Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
Study NCT03585361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEWs and volunteers track PPFP
Description: HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
Study NCT02634216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capros
Description: 250 mg BID
Study NCT00956449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 dose of Influenza Vaccine Surface Antigen, Inactivated
Study NCT01706445 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Other
Description: inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
Study NCT00430625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV ®,
Description: Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
Study NCT02646670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: - In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
Study NCT02646670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: - In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
Study NCT02646670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab and Aflibercept
Description: - The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Study NCT02646670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept and ranibizumab
Description: - In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
Study NCT00562250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, once daily, single dose
Study NCT03170102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Building capacity through education
Description: Participants engaged in 2 webinars and 3 online discussions following reading selected material.
Study NCT02538237 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
Study NCT02538237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2% mouthwash
Study NCT04022031 — intervention group
Intervention type: DRUG
Intervention: Chinese patent medicine
Description: Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
Study NCT00562250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablets, Oral, 4 mg, once daily, single dose
Study NCT02626208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestorone®/Estradiol Contraceptive Vaginal Ring
Description: Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
Study NCT00562250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin + Glimepiride
Description: Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
Study NCT01617434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Study NCT01617434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Study NCT02144350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
Study NCT02144350 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Hyperbaric Air
Description: Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
Study NCT03967925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Sub-cutaneous injection
Study NCT03967925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV infusion 1g x 2
Study NCT03010670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Study NCT01348282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
Study NCT01348282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
Study NCT01752842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Study NCT01752842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for fenofibrate
Study NCT03900559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines
Description: NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes.
Study NCT01053546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
Study NCT01053546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study
Study NCT01053546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study NCT01937130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Study NCT01937130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01135953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
Study NCT01135953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).